financetom
Business
financetom
/
Business
/
Emami enters health juice segment with 26% stake in Axiom Ayurveda
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Emami enters health juice segment with 26% stake in Axiom Ayurveda
Sep 28, 2023 8:21 AM

In a strategic move aimed at diversifying its product portfolio, FMCG major Emami Ltd on Thursday (September 28) announced its entry into the juice category.

Share Market Live

NSE

Emami has achieved this expansion through a significant investment in Axiom Ayurveda Pvt Ltd and its associated companies, acquiring a 26 percent equity stake in the company, the financial details of which remain undisclosed.

Axiom Ayurveda markets a range of beverage products under the brand name, AloFrut. Its juices are a nutritious blend of aloe vera pulp and other fruits. Aloe vera is renowned worldwide as a rich source of essential vitamins, minerals, and amino acids. The AloFrut brand offers a selection of unique flavours.

Also Read: Cholamandalam Investment and Finance may launch Rs 2,000 crore QIP today: Exclusive

While AloFrut is a cornerstone of Axiom Ayurveda's business, the company also boasts a distinctive line-up of carbonated beverages, including mocktails and energy drinks. Additionally, Axiom Ayurveda has a presence in the ayurvedic healthcare juice segment under the Jeevan Ras brand.

To support its growing product line and meet increasing demand, the company operates its manufacturing facility in Ambala, Haryana.

Further, Axiom Ayurveda is actively investing in the future, with plans to establish a cutting-edge, fully automated facility in Jammu's Kathua district, at an investment of Rs 160 crore.

AloFrut has already established a robust presence in various market segments, including general trade, government institutions, modern trade, and e-commerce platforms.

Also Read: Change of guard at India Inc on a rise in 2023

Harsha V. Agarwal, Vice Chairman and MD of Emami Ltd, said, "We are delighted to announce our partnership with Axiom Ayurveda through a strategic investment in equity. This marks our entry into the juice category with AloFrut."

Rishabh Gupta, Founder of Axiom Ayurveda Pvt Ltd said, "It is exciting to have Emami come on board as a strategic partner with wide industry experience who shares our vision to make Alofrut a leader brand."

Shares of Emami Ltd ended at Rs 515, up Rs 3, or 0.59 percent, on the BSE.

(Edited by : Shoma Bhattacharjee)

First Published:Sept 28, 2023 5:21 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Qualys Q1 Adjusted Earnings, Revenue Rise; Lifts 2026 Outlook
Qualys Q1 Adjusted Earnings, Revenue Rise; Lifts 2026 Outlook
May 6, 2026
03:18 AM EDT, 05/06/2026 (MT Newswires) -- Qualys ( QLYS ) reported Q1 adjusted earnings late Tuesday of $1.95 per diluted share, up from $1.67 a year earlier. Analysts polled by FactSet expected non-GAAP EPS of $1.80. Revenue for the quarter ended March 31 was $175.6 million, up from $159.9 million a year ago. Analysts surveyed by FactSet expected $173.7...
Navitas Semiconductor Q1 Adjusted Loss Narrows, Revenue Declines; Issues Q2 Revenue Guidance
Navitas Semiconductor Q1 Adjusted Loss Narrows, Revenue Declines; Issues Q2 Revenue Guidance
May 6, 2026
03:26 AM EDT, 05/06/2026 (MT Newswires) -- Navitas Semiconductor ( NVTS ) reported a Q1 adjusted loss late Tuesday of $0.04 per diluted share, narrowing from a loss of $0.06 a year earlier. Analysts polled by FactSet expected a non-GAAP loss of $0.05 a share. Revenue for the quarter ended March 31 was $8.6 million, down from $14 million a...
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal
May 6, 2026
May 6 (Reuters) - Bayer said on Wednesday that it will buy biopharmaceutical company Perfuse Therapeutics to complement its ophthalmology pipeline. The deal has a potential value of up to $2.45 billion, the company said in a statement, with a $300 million upfront payment and additional development, regulatory and commercial milestone payments based on success criteria. The deal will give...
BRIEF-Adyen CFO Says US Dual Listing Not Company's Focus At The Moment
BRIEF-Adyen CFO Says US Dual Listing Not Company's Focus At The Moment
May 6, 2026
May 6 (Reuters) - Adyen Chief Financial Officer, Ethan Tandowsky, in interview with Reuters: * DUAL LISTING IN US NOT OUR FOCUS AT THE MOMENT * WE HAVE A VERY INTERNATIONAL INSTITUTIONAL INVESTOR BASE, VERY LONG-TERM ORIENTED INVESTOR BASE * NOT LOOKING TO BUY PAYMENTS INFRASTRUCTURE, GROWING IN INORGANIC WAY IN PAYMENTS NOT THE STRATEGY WE SHOULD TAKE Further company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved